A deeper understanding of the predictive role of TMB and PD-1/PD-L1 in treatment with ICI has led to breakthrough treatment options for solid tumors, but their efficacy in hematologic malignancies has been mixed. This evidence concerns the gene CD274 and hematologic disorder.